Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobolimab and Dostarlimab in Advanced Hepatocellular Carcinoma
NCT03680508Phase 2Active, not recruiting
- Sponsor
- University of Hawaiʻi
- Start
- Dec 2019
- Primary completion
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cobolimab, dostarlimab in hepatocellular carcinoma (HCC), sponsored by University of Hawaiʻi. Started Dec 2019; status: active, not recruiting.
02
Drugs
cobolimabdostarlimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03680508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03680508.